HMGB1 and melanoma: To evaluate whether the treatments can trigger immunogenic cell death, the appearance of specific markers, such as the exposure of calreticulin on cell surface and the extracellular release of ATP and HMGB1 [50,51,52], was measured on human melanoma cells treated with (i) AdV-D24 (100 VP/cell), (ii) AdV-D24-ICOSL-CD40L (100 VP/cell), (iii) anti PD-1 (100 μg/mL), (iv) AdV5-D24 (100 VP/cell) combined with anti PD-1 (100 μg/mL), (v) Ad5V-D24-ICOSL-CD40L (100 VP/cell) combined with anti PD-1 (100 μg/mL).